William Blair Starts Chiasma (CHMA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Barclays Starts Chiasma (CHMA) at Overweight
August 10, 2015 7:28 AM EDTBarclays initiated coverage on Chiasma (NASDAQ: CHMA) with an Overweight rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Chiasma click here. For more ratings news on Chiasma click here.
Shares of Chiasma closed at $23.83 yesterday.
... MoreCowen Starts Chiasma (CHMA) at Outperform
August 10, 2015 6:25 AM EDTCowen initiates coverage on Chiasma (NASDAQ: CHMA) with a Outperform rating and a price target of $43.00.
Analyst Ritu Baral commented, "We think Chiasma's TPE-Octreotide will become a key acromegaly treatment in the US/EU. We expect FDA to approve TPE-Octreotide in mid 2016,... More
